Clinical Trial Update: Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 immunotherapy trial for hepatocellular carcinoma aiming to induce an anti-alpha fetoprotein response was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Nantes University Hospital | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED